31- Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor
alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89–91. - Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necro-
sis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut.
1993;34(12):1705–9. - Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentra-
tions of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut.
1991;32(8):913–7. - Remicade (R) [package insert]. Horsham, PA: Jansenn Biotech; 2013.
- Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for
induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. - Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-
term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
Inflamm Bowel Dis. 2012;18(2):201–11. - Humira (R) [package insert]. North Chicago, IL: AbbVie; 2016.
- Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al.
Adalimumab for induction of clinical remission in moderately to severely active ulcerative
colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7. - Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al.
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe
ulcerative colitis. Gastroenterology. 2012;142(2):257–65.e1-3. - Wolf D, D’Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, et al.
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moder-
ately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40(5):486–97. - Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, et al. Four-year
maintenance treatment with adalimumab in patients with moderately to severely active ulcer-
ative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–80. - Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with
active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind,
placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964–75. - Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in
patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the
GO-FORWARD study. Ann Rheum Dis. 2010;69(6):1129–35. - Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab,
a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every
four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week
results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of goli-
mumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis
Rheum. 2009;60(8):2272–83. - Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab
in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha
inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled,
phase III trial. Lancet. 2009;374(9685):210–21. - Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, et al. Golimumab admin-
istered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the
GO-RAISE study. Ann Rheum Dis. 2012;71(5):661–7. - Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al.
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results
from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–17. - Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous goli-
mumab induces clinical response and remission in patients with moderate-to-severe ulcerative
colitis. Gastroenterology. 2014;146(1):85–95; quiz e14-5. - Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous
golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology. 2014;146(1):96–109.e1.
2 Antitumor Necrosis Factor Agents inflUlcerative Colitis